Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advances examine located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://christopheri909xzc2.p2blogs.com/profile